Numerous studies suggest that second-generation drugs such as alectinib, ceritinib, brigatinib, and ensatinib may be more effective than chemotherapy when treating NSCLC patients with no response to first-generation ALK inhibitors (64, 156–158). The gene discussed is ALK; the disease is non-small cell lung carcinoma.